368 related articles for article (PubMed ID: 31494530)
1. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Ott PA; Elez E; Hiret S; Kim DW; Morosky A; Saraf S; Piperdi B; Mehnert JM
J Clin Oncol; 2017 Dec; 35(34):3823-3829. PubMed ID: 28813164
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin CM; Awad MM; Navarro A; Gottfried M; Peters S; Csőszi T; Cheema PK; Rodriguez-Abreu D; Wollner M; Yang JC; Mazieres J; Orlandi FJ; Luft A; Gümüş M; Kato T; Kalemkerian GP; Luo Y; Ebiana V; Pietanza MC; Kim HR;
J Clin Oncol; 2020 Jul; 38(21):2369-2379. PubMed ID: 32468956
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
Gadgeel SM; Pennell NA; Fidler MJ; Halmos B; Bonomi P; Stevenson J; Schneider B; Sukari A; Ventimiglia J; Chen W; Galasso C; Wozniak A; Boerner J; Kalemkerian GP
J Thorac Oncol; 2018 Sep; 13(9):1393-1399. PubMed ID: 29775808
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.
Mountzios G; Emmanouilidis C; Vardakis N; Kontopodis E; Hatzidaki D; Popis E; Karachaliou N; Kotsakis A; Agelidou M; Georgoulias V
Lung Cancer; 2012 Jul; 77(1):146-50. PubMed ID: 22418242
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
Ramalingam SS; Foster J; Gooding W; Evans T; Sulecki M; Belani CP
Cancer; 2010 Mar; 116(5):1344-9. PubMed ID: 20082454
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
Jalal S; Bedano P; Einhorn L; Bhatia S; Ansari R; Bechar N; Koneru K; Govindan R; Wu J; Yu M; Schneider B; Hanna N
J Thorac Oncol; 2010 Dec; 5(12):2008-11. PubMed ID: 21102263
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
Nogami N; Tokito T; Zenke Y; Satouchi M; Seto T; Saka H; Ohtani J; Han S; Noguchi K; Nishio M
Invest New Drugs; 2024 Feb; 42(1):136-144. PubMed ID: 38300341
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
Horn L; Dahlberg SE; Sandler AB; Dowlati A; Moore DF; Murren JR; Schiller JH
J Clin Oncol; 2009 Dec; 27(35):6006-11. PubMed ID: 19826110
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
16. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Chiang AC; Sequist LVD; Gilbert J; Conkling P; Thompson D; Marcoux JP; Gettinger S; Kowanetz M; Molinero L; O'Hear C; Fassò M; Lam S; Gordon MS
Clin Lung Cancer; 2020 Sep; 21(5):455-463.e4. PubMed ID: 32586767
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
18. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
Arriola E; Wheater M; Galea I; Cross N; Maishman T; Hamid D; Stanton L; Cave J; Geldart T; Mulatero C; Potter V; Danson S; Woll PJ; Griffiths R; Nolan L; Ottensmeier C
J Thorac Oncol; 2016 Sep; 11(9):1511-21. PubMed ID: 27296105
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
20. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
